Literature DB >> 2869480

The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.

I P Donald, S P Wilkinson.   

Abstract

The use of sulphasalazine in inflammatory bowel disease is often limited by intolerance or allergy. In previous studies 5-aminosalicylic acid (5ASA), the active ingredient of sulphasalazine, coated with an acrylic resin, has been shown to be as effective as sulphasalazine in maintaining remission. In this study coated 5ASA was given to 37 patients intolerant or allergic to sulphasalazine. Thirty-three patients have tolerated 5ASA satisfactorily, and most experienced improved control of their disease. Four patients reported similar side effects with sulphasalazine and 5ASA.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2869480      PMCID: PMC2418520          DOI: 10.1136/pgmj.61.722.1047

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  8 in total

1.  Exacerbation of diarrhoea and pain in patients treated with 5-aminosalicylic acid for ulcerative colitis.

Authors:  C A Austin; P A Cann; T H Jones; C D Holdsworth
Journal:  Lancet       Date:  1984-04-21       Impact factor: 79.321

2.  Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth.

Authors:  M J Dew; A D Harries; N Evans; B K Evans; J Rhodes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-02

3.  Congenital cytomegalovirus infection.

Authors: 
Journal:  Lancet       Date:  1983-04-09       Impact factor: 79.321

4.  National Cooperative Crohn's Disease Study: results of drug treatment.

Authors:  R W Summers; D M Switz; J T Sessions; J M Becktel; W R Best; F Kern; J W Singleton
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

5.  A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

Authors:  A S Dissanayake; S C Truelove
Journal:  Gut       Date:  1973-12       Impact factor: 23.059

6.  Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

Authors:  A K Azad Khan; D T Howes; J Piris; S C Truelove
Journal:  Gut       Date:  1980-03       Impact factor: 23.059

7.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

8.  An oral preparation to release drugs in the human colon.

Authors:  M J Dew; P J Hughes; M G Lee; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

  8 in total
  7 in total

Review 1.  Pharmacology and pharmacokinetics of 5-aminosalicylic acid.

Authors:  U Klotz; K E Maier
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

Review 2.  Medical treatment of ulcerative colitis: scoring the advances.

Authors:  C J Hawkey; A B Hawthorne
Journal:  Gut       Date:  1988-10       Impact factor: 23.059

3.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

4.  Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?

Authors:  I M Nakshabendi; A Duncan; R I Russell
Journal:  Postgrad Med J       Date:  1992-03       Impact factor: 2.401

5.  Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.

Authors:  S A Riley; V Mani; M J Goodman; M E Herd; S Dutt; L A Turnberg
Journal:  Gut       Date:  1988-05       Impact factor: 23.059

Review 6.  Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

Review 7.  Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.

Authors:  A Prakash; A Markham
Journal:  Drugs       Date:  1999-03       Impact factor: 11.431

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.